# **Structural and Immunochemical Characterization of the Type VIII Group B** *Streptococcus* Capsular Polysaccharide\*

(Received for publication, July 5, 1995, and in revised form, February 7, 1996)

Grigorij Kogan‡§, Dušan Uhrín‡§, Jean-Robert Brisson‡, Lawrence C. Paoletti¶, April E. Blodgett¶, Dennis L. Kasper¶, and Harold J. Jennings‡\*\*

From the ‡Institute for Biological Sciences, National Research Council of Canada, Ottawa, Ontario, K1A 0R6, Canada, the ¶Channing Laboratory, Brigham and Women's Hospital, and the ¶Beth Israel Hospital, Harvard Medical School, Boston, Massachusetts 02115

The type VIII capsular polysaccharide has been isolated and purified from a newly described strain of group B *Streptococcus* which is a leading cause of sepsis and neonatal meningitis in Japan. The polysaccharide contains D-glucose, D-galactose, L-rhamnose, and sialic acid in the molar ratio 1:1:1:1. By means of high resolution <sup>1</sup>H nuclear magnetic resonance (<sup>1</sup>H NMR), <sup>13</sup>C NMR, and homo- and heterocorrelated NMR, the repeating unit structure of the type VIII polysaccharide was delineated as the following,

→ 4)-β-D-Glc*p*-(1 → 4)-β-D-Gal*p*-(1 → 4)-β-L-Rha*p*-(1 → 
$$\frac{3}{2}$$
  
 $\alpha$ -NeuAc

Enzymatic studies established this polysaccharide as the first from which sialic acid, linked to a branched  $\beta$ -D-galactopyranosyl residue, is known to be removed by bacterial neuraminidase.

The group B *Streptococcus* (GBS)<sup>1</sup> has long been recognized as a major cause of neonatal sepsis and meningitis (1, 2). GBS strains are classified into serotypes on the basis of their typespecific capsular polysaccharides. The strains isolated from clinical cases usually belong to one of the major capsular types (Ia, Ib, II, and III) (2), but five new serotypes have recently been described: IV, V (3), VI (4), VII, and VIII. Type VIII<sup>2</sup>

<sup>1</sup> The abbreviations used are: GBS, group B *Streptococcus*; ELISA, enzyme-linked immunosorbent assay.

(originally designated type M9 (5)), while not isolated in North America, has been identified with increasing frequency over the last six years among disease-causing isolates in Japan, where it is now a prevalent strain (5).

The structures of the capsular polysaccharides of GBS types Ia, Ib, II, III (6), IV (7), V (8), VI (9), and VII (10) have been elucidated. Despite their structural relatedness they are largely distinct immunologically. We report the isolation, structural analysis, and immunochemical characterization of the type VIII GBS capsular polysaccharide which like all the other type-specific GBS polysaccharides contains terminal sialic acid.

### EXPERIMENTAL PROCEDURES

Bacterial Strains and Isolation of the Type VIII Capsular Polysaccharide—Type VIII GBS strains JM9 Prague No. 130013 and JM9 Prague No. 130672 were kindly provided by Dr. J. Jelínková, Institute of Hygiene and Epidemiology, Prague, Czech Republic. Strain 130013 was used in the production and purification of the type VIII capsular polysaccharide. GBS strains used in adsorption studies, which had been maintained at -70 °C in cultures at the Channing Laboratory, included: 909 (type Ia), H36B (type Ib), 18RS21 (type II), M781 (type III), M15 (acapsular type III), 3139 (type IV), 1169 (type V), and SS1214 (type VI). GBS strain 130013 was grown in a 16-liter fermenter and the type VIII polysaccharide was isolated and purified by methods utilized previously for other GBS polysaccharides (11).

Analytical Methods-The relative molecular weight of the purified type VIII polysaccharide was determined by gel filtration chromatography on a Superose 6 column (Pharmacia) calibrated with dextran standards. The identity and the immunospecificity of the polysaccharide were tested in double diffusion (Ouchterlony) assay and the competition ELISA, respectively, with use of GBS type-specific antisera. The glycose composition of purified polysaccharide was assessed by gas-liquid chromatography of component alditol acetates prepared by acid hydrolysis of capsular polysaccharide, as described below in the section dealing with the determination of the absolute configuration of the component monosaccharides. Total carbohydrate content was determined by the phenol-sulfuric acid assay (12) with galactose used as the standard. Purified capsular polysaccharides were analyzed for protein by the method of Larson et al. (13) and were studied spectrophoto metrically at  $A_{\rm 260}$  for nucleic acids. The presence and quantity of sialic acid were determined by the method of Warren (14) after hydrolysis of the purified polysaccharide with 3% acetic acid (v/v) at 80 °C for 1 h.

The absolute configurations of the monosaccharides were determined by a modification of the method described by Gerwig *et al.* (15). The polysaccharide sample (1 mg) was hydrolyzed with 0.25  $\,$ M sulfuric acid at 100 °C for 20 h, and the hydrolyzate was neutralized with barium carbonate. The sediment was removed by centrifugation and the supernatant was freeze-dried. The lyophilized residue was dissolved in 0.5 ml of (–)-2-butanol, 1 drop of trifluoroacetic acid was added, and the mixture was heated at 80 °C for 16 h. The solvents were removed by evaporation in vacuum and the dried sample was trimethylsilylated using 0.5 ml of *N*,*O*-bis-(trimethylsilyl)acetamide (Pierce) and 0.5 ml of pyridine. The trimethylsilylated (–)-2-butylglycosides of the constituent monosaccharides were analyzed by capillary gas-liquid chromatography using a Varian Saturn II GC-MS instrument equipped with a DB-17 capillary column (0.25 mm x 30 m, film thickness 0.25  $\mu$ m) in the temperature program 150 to 210 °C at 2 °C/min.

<sup>\*</sup> This work was supported in part by United States Public Health Service Grants AI-23339 and AI-25152 from the National Institutes of Health. This is National Research Council of Canada publication 39513. This work was presented in part at the XVIIth International Carbohydrate Symposium, July 17–25, 1994, Ottawa, Canada. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "*advertisement*" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

<sup>\*\*</sup> To whom correspondence should be addressed. Tel.: 613-990-0821; Fax: 613-952-9092.

<sup>§</sup> Permanent address: Institute of Chemistry, Slovak Academy of Sciences, Bratislava, 842 38, Slovakia.

<sup>&</sup>lt;sup>2</sup> The serotype VIII designation for the capsular polysaccharide isolated from group B *Streptococcus* JM9 strains was proposed by a consensus committee comprised of Dr. P. Ferrieri, University of Minnesota Medical School, Minneapolis, MN; Dr. J. Henrichsen, Staten Seruminstitut, Copenhagen, Denmark; Dr. J. Jelínková, Institute of Hygiene and Epidemiology, Prague, Czech Republic; Dr. D. L. Kasper, Harvard Medical School, Boston, MA; and Dr. G. Orefici, Instituto Superiore di Sanità, Rome, Italy. The meeting of this committee was held during the XII Lancefield International Symposium on Streptococci and Streptococcal Diseases in St. Petersburg, Russia, in 1994.





Preparation of the Chemically Modified Type VIII Polysaccharide— Desialylated type VIII polysaccharide was prepared by hydrolysis of the native polysaccharide with 1% acetic acid at 80 °C for 1 h. After dialysis, the contents of the dialysis bag were freeze-dried. Carbodiimide reduction and periodate oxidation of the terminal sialic acid residues in the native type VIII polysaccharide were conducted as described by Jennings *et al.* (16). If required, the modification procedure was repeated several times until a completely derivatized product was obtained, as confirmed by NMR spectroscopy and mass spectrometry.

*Enzymatic Methods*—The relative susceptibilities of the GBS type II, type III, and type VIII polysaccharides to the action of neuraminidase (type II from *Vibrio cholerae*, EC 3.2.1.18, Sigma) were determined in a following manner: 1 ml of a solution of each polysaccharide (1 mg/ml) was treated with 5 milliunits of neuraminidase/mg at 37 °C for 48 h. A 250-µl volume of each sample was then removed and, after the addition of 16 µl of glacial acetic acid (final concentration, 6%) was hydrolyzed for 1 h at 80 °C. The amount of sialic acid released by each treatment was quantified in the thiobarbituric acid assay, as described by Skoza and Mohos (17). In other experiments, 1-ml volumes of solutions of the polysaccharides (1 mg/ml) were treated with 5 or 10 milliunits of neuraminidase/mg at 37 °C; 200-µl aliquotes were collected after 8, 24, 32, 48, and 120 h; and the amount of liberated sialic acid was determined in thiobarbituric acid assay.

Instrumental Methods—All NMR experiments were performed on a Bruker AMX 600 spectrometer using a 5-mm broad band probe with <sup>1</sup>H coil nearest to the sample. <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded at 330 K in D<sub>2</sub>O at pH 7.0. Acetone was used as internal standard, with the CH<sub>3</sub> resonance at 31.07 ppm for <sup>13</sup>C spectra and 2.225 ppm for <sup>1</sup>H spectra. The experiments were conducted without sample spinning. Two-dimensional homo- and heterocorrelated experiments (COSY, TOCSY, NOESY, HMQC) were carried out as described previously (18). HMQC-TOCSY experiment was performed according to Lerner and Bax (19) and <sup>1</sup>H-detected multiple-bond correlation experiment was carried out by the method of Bax and Summers (20). Spin-echo Fourier transformation experiment was conducted using an interleaved decoupling during the spin-echo period (21).

Antisera—Type-specific antisera to polysaccharides of GBS types Ia, Ib, II, and III were obtained by the immunization of New Zealand White rabbits with GBS polysaccharide-tetanus toxoid conjugate vaccines (22–24). Formalin-killed GBS cells of serotypes IV, V, VI, and VIII (strain JM9 Prague No. 130013) were used as whole cell immunogens for the preparation of rabbit antisera by the method of Lancefield *et al.* (25). Rabbit antiserum to *Streptococcus pneumonia* type 14 was prepared by the Staten Seruminstitut (Copenhagen) and obtained through Dako Corp. (Santa Barbara, CA).

Serotype Specificity of Rabbit Antiserum to Strain 1300013—Whole GBS cells grown in Columbia broth (Difco) were used to evaluate the specificity of type VIII antisera. Log phase cells (1.0 ml: approximately 10<sup>8</sup> colony-forming units/ml) were added to rabbit antiserum to type VIII strain 130013 (0.1 ml; diluted 1:10). After 60 min of inoculation at 37 °C, serum was clarified by centrifugation, adjusted to a total volume of 2 ml with 0.9 ml of phosphate-buffered saline containing 0.01% NaN<sub>3</sub>, and sterilized by filtration (filter pore diameter, 0.45  $\mu$ m). Adsorbed serum (initial dilution, 1:200) was added to a 96-well microtiter plate each well of which was coated with 100 ng of purified type VIII capsular polysaccharide linked to poly-L-lysine (2); this preparation was proc-

essed in a standard ELISA, with alkaline phosphatase-conjugated goat anti-rabbit IgG (diluted 1:3,000) as the secondary antibody. Plates were developed for 60 min after addition of the substrate, and  $A_{405}$  was measured with an ELISA reader (Biotek, Winooki, VT). Values were expressed as the percentage of type VIII-specific antibodies adsorbed relative to quantities of antibody in an unadsorbed antiserum control.

*Competition ELISA*—The relative affinities of type VIII antiserum for native, desialylated, and chemically modified type VIII polysaccharides was evaluated in a competition ELISA. Polysaccharide inhibitors were subjected to serial 2-fold dilution, mixed with an equal volume (100  $\mu$ l) of type VIII antiserum (diluted 1:400), and added to type VIII polysaccharide-coated ELISA wells. The latter antiserum, kindly provided by Dr. Patricia Ferrieri of the University of Minnesota, was adsorbed to remove GBS C-protein activity. Alkaline phosphatase-conjugated goat anti-rabbit IgG was used as the secondary antibody at a dilution of 1:3,000, and the plate was incubated at 37 °C for 60 min. Results are expressed as follows: % inhibition =  $[(A_{405} \text{ without inhibitor})/A_{405} \text{ without inhibitor}] \times 100.$ 

### RESULTS

Structural Analysis of GBS Type VIII Polysaccharide—The type VIII capsular polysaccharide preparation was characterized for carbohydrate composition, molecular size, immunological identity, and impurities. Compositional analysis of the type VIII polysaccharide showed that it contained L-rhamnose, Dglucose, D-galactose, and N-acetylneuraminic acid (sialic acid) in 1:1:1:0.9 molar ratio. The sialic acid content was 30% (as determined in the thiobarbituric acid assay) and the  $M_{\rm r}$  was 200,000 (as determined by gel filtration chromatography). In a double diffusion immunoassay, type VIII polysaccharide formed a single line of identity with rabbit antiserum to whole cells of GBS type VIII strain 130013. Type VIII antiserum did not cross-react with purified capsular polysaccharides of types Ia, Ib, and II through VI. The protein content of the purified polysaccharide was <3% (w/w). Spectrophotometric analysis of purified type VIII capsular polysaccharide (1 mg/ml) showed a strong absorbance at 206 nm that is characteristic of carbohydrate: absorbances at 260 and 280 nm were indicative of low residual levels of nucleic acid and protein, respectively. That the type VIII GBS polysaccharide was composed of the tetrasaccharide repeating units was deduced from its <sup>1</sup>H NMR spectrum (600 MHz, 330 K) (Fig. 1) which contained three anomeric signals at 4.857 (unresolved doublet), 4.825 ( $J_{1,2}$  = 7.3 Hz), and 4.740 ppm ( $J_{1,2}$  = 7.4 Hz) in the ratio 1:1:1, as well as the signals at 2.734 and 1.822 ppm of the equatorial and axial H-3 of  $\alpha$ -linked N-acetyl-D-neuraminic acid, respectively, whose integration was consistent with the presence of one sialic acid residue in the repeating unit. The presence of a tetrasaccharide repeating unit was also confirmed by analysis of the <sup>13</sup>C NMR spectrum of the polysaccharide (150 MHz, 330 K) which exhibited only three signals in the anomeric region at



FIG. 2. Structure of the native (*top*) and desialylated (*bottom*) type VIII polysaccharide antigens of GBS.

104.49 (1C), 103.41 (1C), and 101.38 ppm (2C), but the last signal was shown to contain two overlapping signals as they could be resolved by a spin-echo Fourier transformation experiment. The signal at 101.28 ppm was assigned to the anomeric carbon of the  $\beta$ -L-rhamnopyranosyl residue, while the other one at 101.40 ppm originates from a quarternary carbon, and was thus assigned to C-2 of sialic acid. In addition, signals at 174.29, 52.63, and 39.37 ppm were observed that correspond to C-1, C-5, and C-3 of the sialic acid, as well as those at 175.83 and 22.87 ppm due to its *N*-acetyl group.

The assignment of the <sup>1</sup>H and <sup>13</sup>C NMR signals was performed using homocorrelated two-dimensional COSY, TOCSY, and NOESY techniques, as well as the heterocorrelated HMQC and HMQC-TOCSY methods. The hexose components of the native repeating unit shown in Fig. 2 were designated **a**, **b**, and c according to the sequence of their anomeric signals in the <sup>1</sup>H NMR spectrum. N-Acetylneuraminic acid was designated as unit **d**. The location of the H-2 signal of unit **b** at 3.31 ppm (doublet of doublets with large diaxial couplings  $J_{1,2} = 7.3$  Hz,  $J_{2,3}$  = 9.6 Hz) unambiguously characterized unit **b** as being  $\beta$ -D-glucose. A small coupling constant ( $J_{3,4} \sim 3$  Hz) and very low-field resonance for H-4, together with a large value of  $J_{1,2}$ coupling for H-1c, characterized unit c as  $\beta$ -D-galactose. By elimination, the remaining unit **a** was assigned to be  $\beta$ -Lrhamnose. Because of the mannopyranosyl configuration of the rhamnose ring, it was impossible to determine its anomeric configuration on the basis of  $J_{1,2}$  value. However, NOESY experiments (Table I) showed that the anomeric protons of all the sugar units had cross-peaks with their respective H-3 and H-5 resonances. This finding indicated that the rhamnopyranosyl residue had the  $\beta$ -anomeric configuration as well. The complete assignment of the <sup>1</sup>H and <sup>13</sup>C NMR signals of the native and desialylated type VIII GBS polysaccharide are presented in Tables II and III, respectively.

The sequence of monosaccharides in the repeating unit of both the native and desialylated type VIII GBS polysaccharides were established from separate analyses of their two-dimensional-NOESY spectra (18), and the NOE data (Table I) are consistent with their structures shown in Fig. 2. Independent confirmation of the sequence of monosaccharides in the repeating unit of the desialylated polysaccharide was also obtained using an <sup>1</sup>H-detected multiple-bond correlation experiment which showed cross-peaks between C-1a and H-4c, C-1b and H-4a, as well as between C-1c and H-4b. These long-range correlations are in agreement with the substitution pattern established by the NOESY experiment. Additional evidence for the position of sialylation (O-3) to galactose was also obtained from the downfield displacements exhibited by the H-3 (Table II) and C-3 (Table III) signals of galactose on desialylation of the native type VIII polysaccharide.

Immunological Properties—Rabbit antiserum to whole type VIII cells was determined by adsorption experiments to be

TABLE I Nuclear Overhauser enhancement (NOE) cross-signals for the type VIII GBS capsular polysaccharide

Resonance	Observed NOE			
H-1 <b>a</b>	H-2a, H-3a, H-5a, H-4b			
H-1 <b>b</b>	H-3 <b>b</b> , H-5 <b>b</b> , H-4 <b>c</b>			
H-1 <b>c</b>	H-3c, H-5c, H-4a			
H-3 <sub>ax</sub> d	H-3 <b>c</b>			
ax				

specific for GBS type VIII strains. Type VIII strains 130013 and 130672 bound >90% of type VIII polysaccharide-specific antibodies, whereas <30% of type VIII polysaccharide-specific antibodies were adsorbed with strains of other GBS serotypes.

Competition ELISA revealed that rabbit antiserum to whole cells of type VIII strain 130013 had high affinity for the native type VIII polysaccharide. The concentration of native type VIII polysaccharide that resulted in a 50% inhibition of the binding of type VIII-specific antiserum was 2.8  $\mu$ M (Fig. 3). Desialy-lated, periodate oxidized/borohydride reduced, or carbodiimide-reduced type VIII polysaccharide failed to inhibit binding of type VIII-specific antiserum even when used at a concentration of 0.5 mM (Fig. 3).

Susceptibility to Neuraminidase—The susceptibility of sialic acid to removal by neuraminidase or acid treatment varies among the known GBS type-specific polysaccharides. Unlike the others, type II polysaccharide is resistant to removal of sialic acid by neuraminidase. This resistance of the type II polysaccharide to neuraminidase cleavage has been believed to be a result of the unique position of sialic acid directly linked to galactose in the backbone. The sialic acid residue in the proposed type VIII polysaccharide structure is similarly situated. However, in contrast to the type II polysaccharide, the rate of release of free sialic acid from the type VIII and type III polysaccharides was similar over a 120-h period (Table IV). As previously shown, the type II polysaccharide remained resistant to neuraminidase digestion. The optimal specific activity of neuraminidase resulting in >80% release was 5 milliunits/mg of type III polysaccharide and 10 milliunits/mg of type VIII polysaccharide.

#### DISCUSSION

The structure of the type VIII polysaccharide represents a different motif from previously studied capsular polysaccharides of GBS. Capsular polysaccharides of types Ia, Ib, II, III, IV, V, and VII are all composed of D-galactose, D-glucose, Nacetyl-D-glucosamine, and N-acetylneuraminic acid and contain complex repeating units built from five to seven monosaccharides. The type VIII polysaccharide is not only the first GBS capsular polysaccharide composed of tetrasaccharide repeating units, but is also unique in that  $\beta$ -L- rhamnopyranosyl residues replace the 2-acetamido-2-deoxy-β-D-glucopyranosyl residues found in all other GBS type-specific polysaccharides except type VI (9). The overall structure of the type VIII polysaccharide most closely resembles that of the type II polysaccharide (26) in that the D-galactopyranosyl residues are situated in the backbone rather than in the side chains, the latter being the case in all other types (6-10). Like all the other GBS capsular polysaccharides, the type VIII polysaccharide has terminal sialic acid residues linked to O-3 of D-galactopyranosyl residues.

Although it shares structural features with other GBS polysaccharides, the type VIII polysaccharide is antigenically distinct. No significant cross-reactions were detected by type VIII-specific ELISA after adsorption of type VIII-specific rabbit antiserum with GBS organisms of heterologous serotypes. The lack of cross-reactions among the GBS polysaccharides (7, 8, 28) indicates that sialic acid is not, in and by itself, an immu-

TABLE II
<sup>1</sup> H NMR chemical shift data for the type VIII GBS capsular polysaccharide (PS) and its desialylated derivative (dsPS)
Other NeuAc signals: NAc 2.046, H7 3.60, H8 3.80, H9 3.85, and H9′ 3.65 ppm.

0						
Sugar residue	H-1	H-2	H-3	H-4	H-5	H-6
$\rightarrow$ 4)- $\beta$ -L-Rha-(1 $\rightarrow$						
PS	4.857	4.10	3.82	3.63	3.48	1.371
dsPS	4.854	4.08	3.82	3.62	3.50	1.374
$\rightarrow$ 4)- $\beta$ -D-Glc-(1 $\rightarrow$						
PS	4.825	3.31	3.68	3.60	3.52	3.92,3.80
dsPS	4.656	3.39	3.66	3.61	3.50	3.95,3.81
$\rightarrow$ 4)- $\beta$ -D-Gal-(1 $\rightarrow$ 3						
PS	4.740	3.67	4.20	4.15	3.71	3.78,3.71
dsPS	4.669	3.61	3.77	4.16	3.71	3.83,3.77
$\alpha$ -NeuAc-(2 $\rightarrow$						
PS			1.822(ax)	3.71	3.81	3.61
			2.734(eq)			

TABLE III

<sup>13</sup>C NMR chemical shift data for the type VIII GBS capsular polysaccharide (PS) and its desialylated derivative (dsPS) Other NeuAc signals: NAc(CO) 175.83, NAc(CH<sub>2</sub>) 22.87, C7 69.12, C8 72.81, and C9 63.64 ppm.

		3	,	I I		
Sugar residue	C-1	C-2	C-3	C-4	C-5	C-6
$\rightarrow$ 4)- $\beta$ -L-Rha-(1 $\rightarrow$						
PS	101.28	71.39	73.59	82.13	71.54	17.71
dsPS	101.32	71.50	73.62	82.12	71.65	17.78
$\rightarrow$ 4)- $\beta$ -D-Glc-(1 $\rightarrow$						
PS	103.41	74.31	76.44	77.88	75.10	61.92
dsPS	104.42	74.57	76.43	77.75	75.47	61.90
$\rightarrow$ 4)- $\beta$ -D-Gal-(1 $\rightarrow$ 3						
PS	104.49	71.07	76.22	75.67	75.20	61.46
dsPS	104.69	72.95	74.14	77.99	75.34	61.51
$\alpha$ -NeuAc-(2 $\rightarrow$						
PS	174.29	101.40	39.37	69.20	52.63	73.78



FIG. 3. ELISA inhibition of GBS type VIII rabbit antiserum with native (*closed circles*), carbodiimide-reduced (*open circles*), periodate-oxidized/borohydride-reduced (*closed squares*), and desialylated (*open squares*) type VIII polysaccharides. Values are the mean of duplicate determinations.

nodominant epitope. The failure of sialic acid to be immunodominant might be expected in light of its ubiquity in human and animal tissues (29). However, it is only "non-immunodominant" in the classical sense, that is, not being a direct epitope for antibody binding, but its presence is still crucial to the immunospecificity of antibody raised to the native type VIII polysaccharide. This was demonstrated by the inability of desialylated or otherwise chemically modified type VIII polysaccharide to bind to a significant extent to type VIII-specific antibodies. The involvement of sialic acid in the formation of an immunospecific epitope has also been reported for GBS serotypes Ia, II, III, and VI (4, 28), and hypothesized that the explanation for this specificity lies in the ability of sialic acid to

#### TABLE IV

Sialic acid release from GBS capsular polysaccharides treated with neuraminidase

Time of incubation	Percentage of sialic acid release with GBS capsular polysaccharide <sup>a</sup>				
	Type II	Type III	Type VIII		
h					
8	0	66.2	71.4		
24	0	76.9	76.2		
48	0	79.4	100		
120	0	100	100		

<sup>a</sup> Neuraminidase (10 milliunits/mg of polysaccharide).

exert conformational control over the epitopic expression of these polysaccharides.

The epitopic expression based on extended helical domains of polymers of  $\alpha$ -(2 $\rightarrow$ 8)-polysialic acid has been well documented (28, 30, 31). A similar explanation could apply to the epitopic expression of some of the GBS polysaccharides; in the case of the type III polysaccharide, the chain-length dependence (number of repeating units) of the epitope, which is a requirement for extended helical epitopes (28, 32), has been established (33). Evidence for a sialic acid-controlled conformational epitope in the type III polysaccharide was obtained with NMR spectroscopy which revealed significant displacements in chemical shifts of carbon signals remote from sialic acid when the latter was removed (16). Similar displacements in signals in the spectrum of the type VIII polysaccharide have been detected and may indicate the presence of sialic acid-controlled conformational epitope. Both NMR signals of the anomeric carbon (Table III) and anomeric proton (Table II) of the polysaccharide's backbone  $\beta$ -D-glucopyranosyl residue were significantly displaced (1.0 and 0.17 ppm, respectively) when terminal sialic acid was removed. However, attachment of sialic acid directly to the backbone of the type VIII polysaccharide puts it in closer proximity to the backbone than it is in the type III polysaccharide (6, 11). Therefore, for the type VIII polysaccharide, these

displacements may also be attributable to deshielding of the anomeric carbon and proton of the  $\beta$ -D-glucopyranosyl residue by the carboxylate group of the terminal sialic acid.

GBS type II polysaccharide and G<sub>M1</sub> ganglioside (II<sup>3</sup>NeuAcGgOse<sub>4</sub>Cer) are known to have in their structures terminal N-acetylneuraminic acid residues that are linked directly to O-3 of a branched  $\beta$ -D-galactopyranosyl residues that are resistant to treatment with neuraminidase (26, 34, 35). This resistance has been attributed to steric hindrance of the approach of the enzyme because sialic acid is attached directly to O-3 of the backbone  $\beta$ -D-galactopyranosyl residues that have vicinal substituents in position O-2 or O-4 (26). Although the type VIII polysaccharide also exhibits the above structural features, its terminal sialic acid is readily removed with neuraminidase. Obviously this effect is dependent on specific structural features surrounding  $\beta$ -D-galactopyranosyl residues of the type VIII polysaccharide. In this region type VIII polysaccharide differs in structure from both type II polysaccharide and G<sub>M1</sub> ganglioside; the most pronounced difference is that its backbone  $\beta$ -D-galactopyranosyl residue is linked glycosidically to a unique  $\beta$ -L-rhamnopyranosyl residue. It is interesting to speculate that the enzymatic source for the biosynthesis of the rhamnose substitution in the type VIII polysaccharide may have been from the same enzymes used by all GBS to synthesize the common group B-specific cell wall associated polysaccharide which consists of L-rhamnose, D-galactose, D-glucitol, and N-acetyl-D-glucosamine arranged in a complex multiantennary structure of four structurally distinct oligosaccharides (27).

All GBS polysaccharides whose structures have been elucidated possess side chains that are composed of or terminate with sialic acid. Sialic acid has been shown to be a critical virulence component (36) of these organisms by limiting the deposition on cells of C3b for opsonization in the absence of specific antibodies (37). That this distinguishing characteristic has been maintained on all capsular polysaccharides of GBS isolated from human sources, including type VIII, emphasizes the importance of this sugar in GBS pathogenesis.

Acknowledgments-We thank Fred Cooper for the gas chromatography-mass spectroscopy and Jeff Brown for technical assistance.

#### REFERENCES

- 1. Baker, C. J., and Edwards, M. S. (1988) Ann. N. Y. Acad. Sci. 459, 193-202 2. Ferrieri, P. (1990) Rev. Infect. Dis. 12, S394-S400
- 3. Jelínková, J., and Motlová, J. (1985) J. Clin. Microbiol. 21, 361-362
- 4. von Hunolstein, C., D'Ascenzi, S., Wagner, B., Jelínková, J., Alfarone, G.,

Recchia, S., Wagner, M., and Orefici, G. (1993) Infect. Immun. 61, 1272 - 1280

- 5. Murai, T., Inazumi, Y., Sugiyama, M., and Nishiyama, Y. (1992) Zentralbl. Bakteriol. Mikrobiol. Hyg. Abt. 1 Suppl. 22, 467–469 6. Jennings, H. J. (1990) Curr. Top. Microbiol. Immunol. 150, 97–127
- 7. DiFabio, J. L., Michon, F., Brisson, J.-R., Jennings, H. J., Wessels, M. R., Benedí, V.-J., and Kasper, D. L. (1989) Can. J. Chem. 67, 877-882
- 8. Wessels, M. R., DiFabio, J. L., Benedí, V.-J., Kasper, D. L., Michon, F., Brisson, J.-R., Jelínková, J., and Jennings, H. J. (1991) J. Biol. Chem. 266, 6714-6719
- 9. Kogan, G., Uhrín, D., Brisson, J.-R., Paoletti, L. C., Kasper, D. L., von Hunolstein, C., Orefici, G., and Jennings, H. J. (1994) J. Carbohydr. Chem. **13,** 1071–1078
- 10. Kogan, G., Brisson, J-R., Kasper, D. L., von Hunolstein, C., Orefici, G., and Jennings, H. J. (1995) Carbohydr. Res. 277, 1-9
- 11. Wessels, M. R., Pozsgay, V., Kasper, D. L., and Jennings, H. J. (1987) J. Biol. Chem. 262. 8262-8267
- 12. Dubois, M., Gilles, K. A., Hamilton, J. K., Rebers, P. A., and Smith, F. (1956) Anal. Chem. 28, 350-356
- 13. Larson, E., Howlett, E. B., and Jagendorf, A. (1986) Anal. Biochem. 155, 243-248
- 14. Warren, L. (1959) J. Biol. Chem. 234, 1971-1975
- 15. Gerwig, G. J, Kamerling, J. P., and Vliegenthart, J. F. G. (1978) Carbohydr. Res. 62, 349-357
- 16. Jennings, H. J., Lugowski, C., and Kasper, D. L. (1981) Biochemistry 20, 4511-4518
- 17. Skoza, L., and Mohos, S. (1976) Biochem. J. 159, 457-462
- 18. Baumann, H., Tzianabos, A. O., Brisson, J.-R., Kasper, D. L., and Jennings, H. J. (1992) Biochemistry 31, 4081-4089
- Lerner, L., and Bax, A. (1986) J. Magn. Res. 69, 375–380
  Bax, A., and Summers, M. F. (1986) J. Am. Chem. Soc. 108, 2093–2094
- 21. Brown, D. W., Nakashima, T. T., and Rabenstein, D. L. (1981) J. Magn. Res. 45, 302-314
- 22. Paoletti, L. C., Wessels, M. R., Michon, F., DiFabio, J., Jennings, H. J., and Kasper, D. L. (1992) Infect. Immun. 60, 4009-4014
- 23. Wessels, M. R., Paoletti, L. C., Kasper, D. L., DiFabio, J. L., Michon, F., Holme, K., and Jennings, H. J. (1990) J. Clin. Invest. 86, 1428-1433
- 24. Wessels, M. R., Paoletti, L. C., Rodewald, A. K., Michon, F., DiFabio, J., Jennings, H. J., and Kasper, D. L. (1993) Infect. Immun. 61, 4760-4766
- 25. Lancefield, R. C., McCarty, M., and Everly, W. N. (1975) J. Exp. Med. 142, 165 - 179
- 26. Jennings, H. J., Rosell, K.-G., Katzenellenbogen, E., and Kasper, D. L. (1983) J. Biol. Chem. 258, 1793–1798
- 27. Michon, F., Brisson, J.-R., Dell, A., Kasper, D. L., and Jennings, H. J. (1988) Biochemistry 27. 5341-5351
- 28. Jennings, H. J., Katzenellenbogen, E., Lugowski, C., Michon, F., Roy, R., and Kasper, D. L. (1984) Pure Appl. Chem. 56, 893-905
- 29. Corfield, A. P., and Schauer, R. (1982) Cell Biol. Monogr. 10, 5-50
- 30. Jennings, H. J., Roy, R., and Michon, F. (1985) J. Immunol. 134, 2651-2657 31. Brisson, J.-R., Baumann, H., Imberty, A., Perez, S., and Jennings, H. J. (1992)
- Biochemistry 31, 4996-5004 32. Baumann, H., Brisson, J.-R., Michon, F., Pon, R., and Jennings, H. J. (1993)
- Biochemistry 32, 4007-4013 33. Wessels, M. R., Muñoz, A., and Kasper, D. L. (1987) Proc. Natl. Acad. Sci.
- U. S. A. 84, 9170-9174
- 34. van Heyningen, W. E. (1974) Nature 249, 415-417
- 35. Corfield, A. P., and Schauer, R. (1982) Cell Biol. Monogr. 10, 195-262
- 36. Wessels, M. R., Rubens, C. E., Benedµ, V.-J., and Kasper, D. L. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 8983-8987
- 37. Edwards, M. S., Nicholson-Weller, A., Baker, C. J., and Kasper, D. L. (1980) J. Exp. Med. 151, 1275-1287

## Structural and Immunochemical Characterization of the Type VIII Group B Streptococcus Capsular Polysaccharide

Grigorij Kogan, Dusan Uhrín, Jean-Robert Brisson, Lawrence C. Paoletti, April E. Blodgett, Dennis L. Kasper and Harold J. Jennings

J. Biol. Chem. 1996, 271:8786-8790. doi: 10.1074/jbc.271.15.8786

Access the most updated version of this article at http://www.jbc.org/content/271/15/8786

Alerts:

- When this article is cited
- When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts

This article cites 37 references, 14 of which can be accessed free at http://www.jbc.org/content/271/15/8786.full.html#ref-list-1